卖什么
Platform injectable gel based therapeutic for osteoarthritis
商业模式拆解
买家：谁掌握预算？
未核实Eventual payers: health systems/insurers via approved drug; near-term funding by investors (Y Combinator backed).
触发点：什么让他们现在购买？
Chronic osteoarthritis pain where current treatments fall short; TRPV1 agonists limited by burning on administration which the prodrug addresses.
工作流：什么输入变成什么输出？
Lead RM-010: non-opioid TRPV1 prodrug injected intra-articularly into the knee to desensitize pain-signaling nerve fibers; pipeline also covers urology via injectable, instillation and topical routes.
经济账：省了什么，怎么收费？
未核实Pre-revenue biotech; value from advancing RM-010 through preclinical/pre-IND to clinic, then licensing or sale.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2022 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.